Compare Amgen, Inc. (AMGN) vs Quantumscape Corp (QS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Quantumscape Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Quantumscape Corp trades at $6.51 (market cap $4.05B). The key difference: Amgen, Inc. is far larger — about 48.4× Quantumscape Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| AMGN | QS | |
|---|---|---|
Market Cap | $196.12B | $4.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $18.44 |
52-Week Low | $271.18 | $5.96 |
Enterprise Value | $241.41B | $3.21B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
QuantumScape (QS) trades at $6.58, down 4.78% today, with a bearish technical outlook and negative profitability metrics. The company reported a net loss of $435.05 million in 2025, though cash flow improved to a net positive $85.27 million. Recent news highlights a joint research agreement with Honda, providing optimism for solid-state battery development. Analyst consensus is cautious, with 73% hold ratings and no buy recommendations.
The outlook remains speculative due to high cash burn and unproven commercialization. Risks include execution delays and EV market volatility. Upside depends on successful battery deployment, but near-term financial pressure and bearish sentiment suggest cautious investor positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
